SCHEMBL10293168

SCHEMBL10293168

O=C(c1cc2cc(S(=O)(=O)N3CCCCCC3)ccc2[nH]1)N1CCCCC1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 6/20 0.63
HRH3 Q9Y5N1 2/20 0.63
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
MEN1 O00255 1/20 0.63
HCRTR1 O43613 1/20 0.63
KMT2A Q03164 1/20 0.63
MAPT P10636 1/20 0.56
TSHR P16473 2/20 0.55
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53
ATM Q13315 1/20 0.53
MCOLN3 Q8TDD5 2/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293117 1.00 HRH4 (0.63) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL10293280 1.00 HRH4 (0.63) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL8277123 0.92 HRH4 (0.62) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL8277168 0.90 KMT2A (0.59) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL10293172 0.90 KMT2A (0.59) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL10293202 0.90 KMT2A (0.56) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL10293208 0.89 KMT2A (0.60) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL10293190 0.87 KMT2A (0.67) NPC1RAB9AMEN1HCRTR1KMT2A
SCHEMBL10260539 0.87 KMT2A (0.64) HRH4HRH3NPC1RAB9AMEN1
SCHEMBL10293141 0.87 KMT2A (0.53) HRH4HRH3NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C HRH4 576/4885HRH3 925/4885NPC1 1567/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C HRH4 576/4885HRH3 925/4885NPC1 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.